Paper8599861
Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.
Bhagwatwar HP and 3 others. Cancer Chemother Pharmacol, 1996. Cited by 76 papers, by iCite.
Cite this record
ConductScience Library. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Papers, record 8599861. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8599861
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Alkylating | Major topic |
| Busulfan | Major topic |
| Acetamides | |
| Animals | |
| Cell Survival | |
| Chemistry, Pharmaceutical | |
| Drug Stability | |
| HL-60 Cells | |
| Hemolysis | |
| Humans | |
| Injections, Intravenous | |
| Kinetics | |
| Male | |
| Osmolar Concentration | |
| Polyethylene Glycols | |
| Rats | |
| Solubility | |
| Solvents | |
| Water |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P01 CA55164 | NCI NIH HHS | United States | P01CA055164 | PubMed and NIH |
Source NIH RePORTER
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 288488 | Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. | Blood | 1979 | https://conductscience.org/library/papers/288488 | PubMed |
| 2 | 2591002 | Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2591002 | PubMed |
| 3 | 3068034 | Preclinical toxicology and pharmacology of dimethylacetamide, with clinical notes. | Drug Metab Rev | 1988 | https://conductscience.org/library/papers/3068034 | PubMed |
| 4 | 2659102 | Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. | Blood | 1989 | https://conductscience.org/library/papers/2659102 | PubMed |
| 5 | 2791192 | Pharmacokinetics of high-dose busulfan in children. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2791192 | PubMed |
| 6 | 14076497 | USE OF NONAQUEOUS SOLVENTS IN PARENTERAL PRODUCTS. | J Pharm Sci | 1963 | https://conductscience.org/library/papers/14076497 | PubMed |
| 7 | 2824032 | Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. | Cancer Res | 1987 | https://conductscience.org/library/papers/2824032 | PubMed |
| 8 | 9518161 | Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples. | J Chromatogr B Biomed Sci Appl | 1997 | https://conductscience.org/library/papers/9518161 | PubMed |
| 9 | 5235190 | Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia. | Br Med J | 1968 | https://conductscience.org/library/papers/5235190 | PubMed |
| 10 | 4900650 | Chemotherapy of chronic myelocytic leukemia. | Semin Hematol | 1969 | https://conductscience.org/library/papers/4900650 | PubMed |
| 11 | 3523241 | Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. | N Engl J Med | 1986 | https://conductscience.org/library/papers/3523241 | PubMed |
| 12 | 6933002 | Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. | Cancer Res | 1980 | https://conductscience.org/library/papers/6933002 | PubMed |
| 13 | 2653406 | Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukaemia in accelerated or blastic phase. | Br J Haematol | 1989 | https://conductscience.org/library/papers/2653406 | PubMed |
| 14 | 4612168 | Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. | J Natl Cancer Inst | 1974 | https://conductscience.org/library/papers/4612168 | PubMed |
| 15 | 6355849 | Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. | N Engl J Med | 1983 | https://conductscience.org/library/papers/6355849 | PubMed |
| 16 | 6953987 | Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. | Blood | 1982 | https://conductscience.org/library/papers/6953987 | PubMed |
| 17 | 2060084 | Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/2060084 | PubMed |
| 18 | 14005853 | A phase I study of dimethylacetamide. | Cancer Chemother Rep | 1962 | https://conductscience.org/library/papers/14005853 | PubMed |
| 19 | 1054609 | Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. | Blood | 1975 | https://conductscience.org/library/papers/1054609 | PubMed |
| 20 | 7919328 | Busulfan bioavailability. | Blood | 1994 | https://conductscience.org/library/papers/7919328 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 76 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42001814 | The FDA-approved excipient N,N-dimethylacetamide improves survival and attenuates inflammatory pathways in a murine model of endotoxemia. | Biomed Pharmacother | 2026 | https://conductscience.org/library/papers/42001814 | PubMed |
| 41988138 | Research hotspots and trends in therapeutic drug monitoring of anticancer drugs: a 1990-2024 bibliometric analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/41988138 | PubMed |
| 40514011 | Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience. | Transplant Cell Ther | 2025 | https://conductscience.org/library/papers/40514011 | PubMed |
| 39271948 | A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT). | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/39271948 | PubMed |
| 36966213 | Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy. | Bone Marrow Transplant | 2023 | https://conductscience.org/library/papers/36966213 | PubMed |
| 36710948 | Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients. | Blood Cell Ther | 2022 | https://conductscience.org/library/papers/36710948 | PubMed |
| 36568145 | Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices. | Front Oncol | 2022 | https://conductscience.org/library/papers/36568145 | PubMed |
| 34206798 | Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34206798 | PubMed |
| 28766962 | Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. | Expert Opin Drug Metab Toxicol | 2017 | https://conductscience.org/library/papers/28766962 | PubMed |
| 27722893 | Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation. | Int J Hematol | 2016 | https://conductscience.org/library/papers/27722893 | PubMed |
| 27154848 | Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. | Biol Blood Marrow Transplant | 2016 | https://conductscience.org/library/papers/27154848 | PubMed |
| 26292764 | Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. | Leuk Lymphoma | 2016 | https://conductscience.org/library/papers/26292764 | PubMed |
| 22455797 | Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. | Clin Pharmacokinet | 2012 | https://conductscience.org/library/papers/22455797 | PubMed |
| 21478919 | Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation. | Bone Marrow Transplant | 2012 | https://conductscience.org/library/papers/21478919 | PubMed |
| 21120188 | Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. | Korean J Hematol | 2010 | https://conductscience.org/library/papers/21120188 | PubMed |
| 20577993 | Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. | Environ Mol Mutagen | 2010 | https://conductscience.org/library/papers/20577993 | PubMed |
| 19561406 | Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. | Curr Opin Oncol | 2009 | https://conductscience.org/library/papers/19561406 | PubMed |
| 19361744 | Busulfan in hematopoietic stem cell transplantation. | Biol Blood Marrow Transplant | 2009 | https://conductscience.org/library/papers/19361744 | PubMed |
| 18489993 | Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18489993 | PubMed |
| 18339423 | Altered gene expression in busulfan-resistant human myeloid leukemia. | Leuk Res | 2008 | https://conductscience.org/library/papers/18339423 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8599861
GET https://conductscience.org/api/papers/v1/8599861/references?page=2